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ECONOMIC AND OUTCOMES ISSUES IN
CARDIOVASCULAR DISEASE
eVA.
ECONOMIC OUTCOMES OF CAROTID
ENDARTERECTOMY FOR STROKE
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American Heart Association Guidelines establish accept-
able limits of carotid endarterectomy (CEA) postopera-
tive morbidity/mortality at 7-9%. Based on these stan-
dards, early CEA (within 30 days of non-disabling
stroke) has been safely performed. However, early CEA is
not standard practice at many institutions. Decreasing the
interval between stroke and surgery (SSI) may decrease
the risk of recurrent stroke in the SSI and resource utiliza-
tion through elimination of interval anticoagulation.
OBJECTIVE: Clinical and economic outcomes of early
and delayed (beyond 30 days) CEA in non-disabling
stroke patients were examined.
METHODS: Sixty-three patients were identified through
a physician's office registry, the Thomas Jefferson Univer-
sity Hospital's clinical financial management system, and
chart review as having had CEA for non-disabling stroke
between November, 1991 and December, 1996. Details
regarding SSI and perioperative (surgery to discharge)
stroke, myocardial infarction (MI), and death were ob-
tained from charts. Inpatient costs were extracted from
clinical financial management systems for early and de-
layed group patients. Interval anticoagulation costs were
estimated using established models in atrial fibrillation.
RESULTS:
% > 2 comorbidities
Perioperative stroke rate
MIIDeath rate
Early Patients
(n = 43)
63% (27)
2.3% (1)
0% (0)
Delayed Patients
(n = 20)
37% (7)
5% (1)
5% (1)
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The average total cost of hospitalization per delayed
group patient was $US11,337 (95% CI $9,217-$13,943).
The cost of initial hospitalization and interval anticoagu-
lation per delayed group patient was estimated to be
$US3,119. The estimated total cost of treatment per pa-
tient in the early and delayed groups, respectively, was
$US13,791 and $US14,455.
CONCLUSION: This study suggests that early CEA can
be performed with acceptable peri operative morbidity
rates in selected non-disabling stroke patients. Decreasing
the length of the SSI decreases the recurrent stroke risk
and interval anticoagulation resource utilization.
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COST-EFFECTIVENESS AND ECONOMIC
EFFICIENCY: THE CASE OF STATIN
THERAPY IN SECONDARY PREVENTION
OF CORONARY HEART DISEASE
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Health-care case management places pressure on decision
makers to adopt treatment strategies that promote eco-
nomic efficiency and hence profitability. Traditional cost-
effectiveness analysis (CEA), where the objective is to cal-
culate cost-effectiveness ratios, can better inform decision
making in markets where prices and efficacy vary widely.
However, the threshold at which a given therapy be-
comes economically efficient relative to competing thera-
pies is not evident from cost-effectiveness ratios alone.
OBJECTIVE: To illustrate the use of spatial techniques
for identifying efficient treatment options, using statin
therapy in secondary prevention of coronary heart dis-
ease (CHD) as a case study.
METHODS: We used a Markov model of CHD epidemi-
ology and treatment to estimate cost-effectiveness of 13
statin regimens versus no therapy in secondary preven-
tion of CHD. Comparative efficacy was assessed using
data from a recent trial (CURVES) that included these
regimens. Patients were assumed to have a history of
CHD with risk factors similar to those observed in the
trial. CHD event risk was estimated using new subse-
quent-event risk equations from the Framingham Heart
Study. Effectiveness was measured alternatively as gain in
life expectancy and CHD events averted.
RESULTS: At usual starting doses, atorvastatin therapy
provided the largest life expectancy gain and CHD event
avoidance at the lowest cost per life-year gained ($12,900
and $23,400 for men and women, respectively), followed
by simvastatin ($17,700 and $31,700), lovastatin ($18,800
and $33,700), pravastatin ($22,600 and $40,200), and flu-
vastatin ($23,800 and $42,000). Any desired level of effec-
tiveness can be obtained at lowest cost with atorvastatin.
CONCLUSION: Economic efficiency is enhanced when
atorvastatin is used to treat some or all patients requiring
sratin therapy in secondary prevention of CHD.
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ADHERENCE TO HYPERTENSION THERAPY:
THE EFFECT OF INITIAL DRUG CHOICE
Caro j]', Speckrnan jl,', Salas MI, Raggio G',JacksonJD2
'Caro Research, Boston, MA, USA; 2Bristol-Myers Squibb,
Princeton, NJ, USA
Clinical trials of antihypertensive medications have gen-
erally found good efficacy and similar safety among the
many available agents. However, non-experimental stud-
ies of hypertension have often found that a large propor-
tion of hypertensive patients remain uncontrolled, per-
haps due to lack of adherence with therapy. The results
of clinical trials, therefore, may not entirely accord with
the realities of hypertension treatment.
OBJECTIVE: To determine if adherence with antihyper-
tensive therapy depends on the initial drug prescribed.
METHODS: A large database (over 3 million drug dis-
pensings) containing information on 79,591 hypertensive
patients in Saskatchewan, Canada, was used to analyze
the patterns of drug therapy. The medication regimen, in-
cluding changes and lack of adherence (temporary and
permanent), was deduced from information on hospital-
izations, pharmacological information on each agent
(e.g., minimum daily dosage), and drug dispensings. Ka-
plan-Meier survival analysis was used to compare cumu-
lative persistence rates. Cox regression was used for con-
trolled analysis.
RESULTS: Among 22,198 newly diagnosed hypertensive
patients, over 20% discontinued medication within the
first year. The rates varied by initial drug class, from
26% among patients beginning with a diuretic to 17%
when an angiotensin converting enzyme inhibitor was
used first (p > 0.001). This divergence remained signifi-
cant when controlling for baseline differences among the
groups in age, sex, and prior level of medicalization.
Changes in the therapeutic regimen were also associated
with increasing levels of discontinuation (p < 0.05).
CONCLUSION: These results suggest that the choice of
initial drug, and changes made to the therapeutic regi-
men, may be important determinants of patient adher-
ence to therapy. In this case, physicians should consider
results of actual practice studies, together with clinical
trial results, in making therapeutic choices.
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